Lingohr & Partner Asset Management Gmb H Halozyme Therapeutics, Inc. Transaction History
Lingohr & Partner Asset Management Gmb H
- $57.3 Million
- Q3 2025
A detailed history of Lingohr & Partner Asset Management Gmb H transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Lingohr & Partner Asset Management Gmb H holds 2,883 shares of HALO stock, worth $196,188. This represents 0.37% of its overall portfolio holdings.
Number of Shares
2,883
Previous 2,883
-0.0%
Holding current value
$196,188
Previous $211,000
-0.0%
% of portfolio
0.37%
Previous 0.05%
Shares
1 transactions
Others Institutions Holding HALO
# of Institutions
632Shares Held
128MCall Options Held
408KPut Options Held
384K-
Black Rock Inc. New York, NY17.6MShares$1.2 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$833 Million0.01% of portfolio
-
State Street Corp Boston, MA5.94MShares$404 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA3.47MShares$236 Million0.03% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.4MShares$231 Million3.92% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.48B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...